Alpine Immune Sciences, Inc. Financials

Market Capitalization $1.03 Billion as of Jan. 1, 2024

Valuations Metrics as of Jan. 25, 2025

Trailing PE	22.06
Forward PE
Price to Sales TTM	CHF7.45
Price to Book MRQ	CHF0.92
Enterprise to Revenue	7.77
Enterprise to EBITDA

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	33.49%
Operating Margin	75.63%
Return on Assets TTM	4.85%
Return on Equity TTM	3.41%

Income Statement

Revenue TTM	CHF8,764,000
Revenue per Share TTM	CHF1.01
Quarterly Revenue Growth	287.20%
Gross Profit TTM	CHF0
EBITDA	CHF0
Net Income to Common TTM	CHF2,935,000
Diluted EPS TTM	CHF0.34
Quarterly Earnings Growth YoY	1730.40%

Balance Sheet

Total Cash MRQ	CHF801,000
Total Cash per Share MRQ	CHF0.09
Total Debt MRQ	CHF
Total Debt to Equity MRQ	3.25
Current Ratio MRQ	0.67
Book Value per Share MRQ	CHF8.12

Cash Flow

Operating Cash Flow TTM	CHF3,346,000
Levered Free Cash Flow TTM	CHF4,098,125

ALPN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	8,709,900
Float Shares	1,596,612
Avg 10 Volume	1,490
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	62.58%
% Held by Institutions	1.65%

Stock Price Summary

Beta	0.30
Fifty Two Week Low	CHF7.00
Fifty Two Week High	CHF8.10
Fifty Two Week Change	-0.66%
Day 50 MA	CHF7.51
Day 200 MA	CHF7.66

Dividends and Splits

Forward Annual Dividend Rate	CHF12.00
Forward Annual Dividend Yield	158.94%
Trailing Annual Dividend Rate	CHF3.00
Trailing Annual Dividend Yield	39.74%
Payout Ratio	0.00%
Dividend Date	2023-09-27
Ex Dividend Date	2023-09-25
Last Split Factor
Last Split Date	2004-09-02